Price (delayed)
$0.99
Market cap
$45.14M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.84
Enterprise value
$69.3M
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica's late-stage product candidate, VP-102, is in development to treat molluscum contagiosum (molluscum), common warts and
There are no recent dividends present for VRCA.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.